are also described with other suicide gene approaches (HSV-tk/ GCV or CD20/Rituximab). The aims of this work were 1/ to better characterize the CID responsiveness and 2/ to evaluate a new means to improve the treatment. We generated, by retroviral transduction (SFG.iCasp9.2A.CD19), iC9/CD19+ Jurkat, CEM and HUT cell lines. Transduction effi ciency was 57.7±13.6 (n=3). After induction of apoptosis with CID, GMC were effi ciently eliminated. However, we found that 1.47% ± 0.67% (n=5) of CD19+ MACS-selected escaped after CID in-vitro exposure. GMC were serially exposed to increase the doses (0.1nM to 10nM) of CID to generate resistant cell lines (GMCR). Drug response was assessed by 7-AAD/Annexin V staining and surviving GMC were cloned to isolate GMCR. Compared to sensitive GMC (GMCS), we showed that GMCR are lower CD19 expressers (MFI= 30 fold less). While retroviral vector is based on 2A system, allowing stoichiometric iC9/CD19 proteins production, we hypothesize that GMCR are also the lower iC9 expressers. This has been confi rmed by western blot (WB) for both full length and cleaved iC9. A hypomethylating agent could increase transgenes expression in order to improve iC9 GMC response. A good candidate could be the 5-aza. To assess this hypothesis, CEM-GMCS and -GMCR were treated 4 days with 5-aza (1μM). We have shown by cytometry that 5-aza exposure of CEM-GMCR increase the CD19 expression (MFI= 5 fold more). Moreover, WB analysis confi rms the increase of the iC9 protein expression. As expected, drug response is improved after 5-aza treatment. The percentage of CEM-GMCR mortality induced by CID vs 5-aza+CID was 3.8% vs 62.5% respectively. Stable CD4 expression suggests that transgenes expression has been mainly targeted. In conclusion, we have generated CID resistant T cell lines and determined that low responders are iC9/CD19 low expressers. Moreover, we have shown that 5-aza treatment improves the expression of transgenes and leads to restore the CID killing. This approach can be applied in further clinical trials in order to improve killing of iC9 expressing T cells used in hematopoietic transplantation or to secure cell therapies.
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Adapting the Spontaneous Canine Osteosarcoma Model for T-Cell Therapy
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Encouraging data have emerged from adoptive T-cell therapies in advanced forms of cancer. Anti-tumor immunity is found in tumor infi ltrating lymphocytes as well as engineered T cells where exogenous expression of a chimeric antigen receptor (CAR) confers cancer recognition on the cells. However, present adoptive immunotherapy methods are limited by the need for complex, time consuming manipulation of autologous patient T-cells. The availability of such a treatment using allogeneic cells is currently not possible due to poor persistence of the cells in the host and the potential for graft versus host disease (GvHD). To address these limitations Transcription Activator-Like Effector Nucleases (TALENTM), a novel class of sequence-specifi c nucleases created by the fusion of transcription activator-like effectors (TALEs) to the catalytic domain of an endonuclease, can be used to inactivate one or several genes in primary T cells. TALENsTM permit the effi cient and simultaneous elimination of the endogenous T cell receptor and a cellular target for a lymphodepleting treatment. This approach signifi cantly reduces the risk of GVHD while permitting proliferation and activity of the introduced T lymphocytes in the presence of immunosuppressive drugs. The development of this approach for an off-the-shelf therapeutic T-cell platform will be presented.
